AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JAN 16 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - A group of proinflammatory cytokines may be useful as adjuvants for nasally administered HIV vaccines, researchers in the United States report.
"Safe and potent new adjuvants are needed for vaccines that are administered to mucosal surfaces," according to Curtis P. Bradney and colleagues at Duke University Medical Center's Departments of Medicine, Human Vaccine Institute, and Center for AIDS Research in Durham, North Carolina.
Several interleukins in combination significantly enhanced the efficacy of a vaccine candidate, to a higher degree than other potential adjuvants, Bradney and coauthors found.
The researchers administered an env-based vaccine nasally to BALB/c mice, using interleukin (IL)-1(alpha), IL-12, and IL-18 as adjuvants. After 28 days, serum antiviral antibody titers were significantly higher than those achieved with the same adjuvant-free vaccine, they said.
Moreover, interleukin adjuvants provided better results than cholera toxin (CT), a commonly used mucosal vaccine adjuvant. Serum, saliva, fecal, and vaginal HIV antibody titers in mice were all significantly higher when IL-1(alpha), IL-12, and IL-18 were used in place of cholera toxin, study data showed.
Serum immunoglobulin (Ig)G1 titers were more than four times higher with interleukin ...